BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 28709134)

  • 1. BCR-ABL1-like acute lymphoblastic leukaemia: From bench to bedside.
    Boer JM; den Boer ML
    Eur J Cancer; 2017 Sep; 82():203-218. PubMed ID: 28709134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.
    Boer JM; Steeghs EM; Marchante JR; Boeree A; Beaudoin JJ; Beverloo HB; Kuiper RP; Escherich G; van der Velden VH; van der Schoot CE; de Groot-Kruseman HA; Pieters R; den Boer ML
    Oncotarget; 2017 Jan; 8(3):4618-4628. PubMed ID: 27894077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High incidence of RAS pathway mutations among sentinel genetic lesions of Korean pediatric BCR-ABL1-like acute lymphoblastic leukemia.
    Lee JW; Kim Y; Cho B; Kim S; Jang PS; Lee J; Cho H; Lee GD; Chung NG; Kim M
    Cancer Med; 2020 Jul; 9(13):4632-4639. PubMed ID: 32378810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.
    Oya S; Morishige S; Ozawa H; Sasaki K; Semba Y; Yamasaki Y; Nakamura T; Aoyama K; Seki R; Mouri F; Osaki K; Miyamoto T; Maeda T; Nagafuji K
    Int J Hematol; 2021 Feb; 113(2):285-289. PubMed ID: 32951102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).
    De Keersmaecker K; Graux C; Odero MD; Mentens N; Somers R; Maertens J; Wlodarska I; Vandenberghe P; Hagemeijer A; Marynen P; Cools J
    Blood; 2005 Jun; 105(12):4849-52. PubMed ID: 15713800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting signaling pathways in acute lymphoblastic leukemia: new insights.
    Harrison CJ
    Hematology Am Soc Hematol Educ Program; 2013; 2013():118-25. PubMed ID: 24319172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Kinase-activating Genetic Lesions to Improve Therapy of Pediatric Acute Lymphoblastic Leukemia.
    Franca R; Kuzelicki NK; Sorio C; Toffoletti E; Montecchini O; Poropat A; Rabusin M; Curci D; Paladin D; Stocco G; Decorti G
    Curr Med Chem; 2018; 25(24):2811-2825. PubMed ID: 28748759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.
    Roberts KG; Pei D; Campana D; Payne-Turner D; Li Y; Cheng C; Sandlund JT; Jeha S; Easton J; Becksfort J; Zhang J; Coustan-Smith E; Raimondi SC; Leung WH; Relling MV; Evans WE; Downing JR; Mullighan CG; Pui CH
    J Clin Oncol; 2014 Sep; 32(27):3012-20. PubMed ID: 25049327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications.
    Chiaretti S; Messina M; Grammatico S; Piciocchi A; Fedullo AL; Di Giacomo F; Peragine N; Gianfelici V; Lauretti A; Bareja R; Martelli MP; Vignetti M; Apicella V; Vitale A; Li LS; Salek C; Elemento O; Inghirami G; Weinstock DM; Guarini A; Foà R
    Br J Haematol; 2018 Jun; 181(5):642-652. PubMed ID: 29675955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain.
    van Outersterp I; Tasian SK; Reichert CEJ; Boeree A; de Groot-Kruseman HA; Escherich G; Boer JM; den Boer ML
    Blood; 2024 May; 143(21):2178-2189. PubMed ID: 38394665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiplex reverse transcription-polymerase chain reaction as diagnostic molecular screening of 4 common fusion chimeric genes in Taiwanese children with acute lymphoblastic leukemia.
    Yang YL; Lin SR; Chen JS; Hsiao CC; Lin KH; Sheen JM; Cheng CN; Wu KH; Lin SW; Yu SL; Chen HY; Lu MY; Chang HH; Yen CT; Lin JF; Su YH; Li YP; Lin CY; Jou ST; Lin DT
    J Pediatr Hematol Oncol; 2010 Nov; 32(8):e323-30. PubMed ID: 20930648
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Jain S; Abraham A
    Arch Pathol Lab Med; 2020 Feb; 144(2):150-155. PubMed ID: 31644323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCR/ABL1-Like Acute Lymphoblastic Leukemia: From Diagnostic Approaches to Molecularly Targeted Therapy.
    Płotka A; Lewandowski K
    Acta Haematol; 2022; 145(2):122-131. PubMed ID: 34818644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interphase-FISH screening for eight common rearrangements in pediatric B-cell precursor acute lymphoblastic leukemia.
    Hutspardol S; Pakakasama S; Kanta K; Nuntakarn L; Anurathapan U; Sirachainan N; Songdej D; Sawangpanich R; Tiyasirichokchai R; Rerkamnuaychoke B; Hongeng S
    Int J Lab Hematol; 2013 Aug; 35(4):406-15. PubMed ID: 23190578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
    Roberts KG; Li Y; Payne-Turner D; Harvey RC; Yang YL; Pei D; McCastlain K; Ding L; Lu C; Song G; Ma J; Becksfort J; Rusch M; Chen SC; Easton J; Cheng J; Boggs K; Santiago-Morales N; Iacobucci I; Fulton RS; Wen J; Valentine M; Cheng C; Paugh SW; Devidas M; Chen IM; Reshmi S; Smith A; Hedlund E; Gupta P; Nagahawatte P; Wu G; Chen X; Yergeau D; Vadodaria B; Mulder H; Winick NJ; Larsen EC; Carroll WL; Heerema NA; Carroll AJ; Grayson G; Tasian SK; Moore AS; Keller F; Frei-Jones M; Whitlock JA; Raetz EA; White DL; Hughes TP; Guidry Auvil JM; Smith MA; Marcucci G; Bloomfield CD; Mrózek K; Kohlschmidt J; Stock W; Kornblau SM; Konopleva M; Paietta E; Pui CH; Jeha S; Relling MV; Evans WE; Gerhard DS; Gastier-Foster JM; Mardis E; Wilson RK; Loh ML; Downing JR; Hunger SP; Willman CL; Zhang J; Mullighan CG
    N Engl J Med; 2014 Sep; 371(11):1005-15. PubMed ID: 25207766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study.
    den Boer ML; Cario G; Moorman AV; Boer JM; de Groot-Kruseman HA; Fiocco M; Escherich G; Imamura T; Yeoh A; Sutton R; Dalla-Pozza L; Kiyokawa N; Schrappe M; Roberts KG; Mullighan CG; Hunger SP; Vora A; Attarbaschi A; Zaliova M; Elitzur S; Cazzaniga G; Biondi A; Loh ML; Pieters R;
    Lancet Haematol; 2021 Jan; 8(1):e55-e66. PubMed ID: 33357483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid molecular response to dasatinib in Ph-like acute lymphoblastic leukemia patients with ABL1 rearrangements: case series and literature review.
    Tan KW; Zhu YY; Qiu QC; Wang M; Shen HJ; Huang SM; Cao HY; Wan CL; Li YY; Dai HP; Xue SL
    Ann Hematol; 2023 Sep; 102(9):2397-2402. PubMed ID: 37103615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence.
    Bleckmann K; Schrappe M
    Br J Haematol; 2016 Mar; 172(6):855-69. PubMed ID: 26773444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging BCR/ABL1 Mutations Under Treatment with Tyrosine Kinase Inhibitors in Paediatric Acute Lymphoblastic Leukaemia.
    Molinos-Quintana A; Aquino V; Montero I; Pérez-de Soto C; García-Lozano R; Pérez-Simón JA; Pérez-Hurtado JM
    Acta Haematol; 2015; 134(2):71-5. PubMed ID: 25895602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of molecular responses based on BCR-ABL1% (IS) results from an in-house TaqMan-based qPCR versus Xpert(®) assay in CML patients on tyrosine kinase inhibitor therapy.
    Boeckx N; Laer CV; Roover JD; Wilmsen B; Bruyninckx K; Pauwels S
    Acta Clin Belg; 2015 Aug; 70(4):237-43. PubMed ID: 26166681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.